Ind-Swift Laboratories Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
- July 8, 2026
- Posted by: Kunal Singla
- Category: News
Ind-Swift Laboratories CMP Rs.215. Q1 FY27E revenue Rs.188-216 Cr. PAT estimate Rs.4-5 Cr. 12-month target Rs.248-276.
Ind-Swift Laboratories Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Ind-Swift Laboratories shares trading at Rs.215 against a market capitalisation of Rs.1,928 Cr and a price-to-earnings multiple of 46.6. As a pharmaceuticals and life sciences name on the NSE and BSE, Ind-Swift Laboratories enters the Ind-Swift Laboratories Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
This Ind-Swift Laboratories Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.167 Cr revenue and Rs.9 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.
Get Free Investment Predictions and Ind-Swift Laboratories Research at Univest
About Ind-Swift Laboratories
Ind-Swift Laboratories (NSE: INDSWFTLAB) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Ind-Swift Laboratories Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.172 Cr and net profit of Rs.15 Cr, forming the base against which the Ind-Swift Laboratories Q1 Results FY27 estimates in this article are built. This Ind-Swift Laboratories Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.
Ind-Swift Laboratories Q1 FY27 Estimates
| Metric | Q1 FY27E (Range) | Q1 FY26 Actual | YoY Growth |
|---|---|---|---|
| Revenue (Rs. Cr) | 188-216 | 167 | +20.5% |
| Net Profit / PAT (Rs. Cr) | 4-5 | 9 | -50.0% |
| Results Date | July-August 2026 (indicative) | ||
| 12-Month Target (Uniresearch Estimate) | Rs.248-276 | ||
Key Catalysts to Watch
1. CDMO Pipeline Visibility
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Ind-Swift Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ind-Swift Laboratories share price target or faces renewed pressure.
2. New Product Approvals
New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Ind-Swift Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ind-Swift Laboratories share price target or faces renewed pressure.
3. Capacity Scale-Up
Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Ind-Swift Laboratories’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ind-Swift Laboratories share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Ind-Swift Laboratories’s live price and Q1 FY27 result updates.
Key Risks to the Ind-Swift Laboratories Q1 Results FY27 Outlook
- Pricing pressure in key export markets, particularly the US generics segment.
- Regulatory or plant compliance issues affecting supply continuity.
- R&D and capacity expansion costs weighing on near-term profitability.
Q4 FY26 Performance Context for the Ind-Swift Laboratories Q1 Results FY27 Print
Ind-Swift Laboratories closed Q4 FY26 with revenue of Rs.172 Cr and net profit of Rs.15 Cr, a year-on-year revenue change of +20.5% and PAT change of -93.2% versus Q4 FY25. This base underpins the Ind-Swift Laboratories Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Ind-Swift Laboratories Q1 Results FY27 commentary once reported.
Technical Analysis Ahead of Ind-Swift Laboratories Q1 Results FY27
Ind-Swift Laboratories shares last traded at Rs.215. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Ind-Swift Laboratories Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Ind-Swift Laboratories Q1 Results FY27 trailing-growth framework points to a range of Rs.221-239 for Ind-Swift Laboratories, contingent on the Ind-Swift Laboratories Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Ind-Swift Laboratories Q1 Results FY27 view for Ind-Swift Laboratories works out to Rs.248-276, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Ind-Swift Laboratories Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Ind-Swift Laboratories Q1 Results FY27 analysis would put Ind-Swift Laboratories in a Rs.279-317 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.
What to Watch in the Ind-Swift Laboratories Q1 Results FY27 Print
- Revenue and PAT versus the Ind-Swift Laboratories Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Ind-Swift Laboratories Q1 Results FY27 narrative.
- Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
- Pricing pressure in key export markets, particularly the US generics segment
Conclusion on Ind-Swift Laboratories Q1 Results FY27
Ind-Swift Laboratories enters the Q1 FY27 results season trading at Rs.215, with the 12-month Uniresearch target range of Rs.248-276 reflecting a tracking with a constructive bias stance. Investors tracking the Ind-Swift Laboratories Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Ind-Swift Laboratories Q1 Results FY27
When are Ind-Swift Laboratories Q1 FY27 results expected?
Ans. Ind-Swift Laboratories’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Ind-Swift Laboratories Q1 FY27 revenue estimate?
Ans. The Uniresearch trailing-growth estimate for Ind-Swift Laboratories’s Q1 FY27 revenue is Rs.188-216 Cr, based on the Q1 FY26 base of Rs.167 Cr.
What is the Ind-Swift Laboratories share price target?
Ans. The 12-month Uniresearch estimate for Ind-Swift Laboratories share price target is Rs.248-276, based on trailing growth and current valuation multiples.
Is Ind-Swift Laboratories a good buy before Q1 FY27 results?
Ans. Ind-Swift Laboratories is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Ind-Swift Laboratories’s Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.
Where can I track Ind-Swift Laboratories share price live?
Ans. Ind-Swift Laboratories share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
